Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Serum soluble ST2 and interleukin-33 levels in patients with pulmonary arterial hypertension.

Literature DB >> 23290950

Serum soluble ST2 and interleukin-33 levels in patients with pulmonary arterial hypertension.

Guido Carlomagno¹, Giancarlo Messalli, Rosa Marina Melillo, Anna Agnese Stanziola, Carla Visciano, Valentina Mercurio, Massimo Imbriaco, Stefano Ghio, Matteo Sofia, Domenico Bonaduce, Serafino Fazio.

Abstract

Entities: Disease Gene Species

Keywords: 6-minute walking distance; 6MWD; Biomarkers; CHF; CMR; Cardiac magnetic resonance; IL-33; N-terminal fragment of pro-B-type natriuretic peptide; NT-proBNP; PAH; PVR; Pulmonary arterial hypertension; RHC; RV; RVEDVi; RVEF; RVESVi; Right ventricular function; ST2; cardiac magnetic resonance imaging; chronic left-sided heart failure; interleukin 33; pulmonary arterial hypertension; pulmonary vascular resistance; right heart catheterization; right ventricle; right ventricular ejection fraction; right ventricular end-diastolic volume index; right ventricular end-systolic volume index; sST2; soluble ST2

Mesh：

Substances：

Year: 2013 PMID： 23290950 DOI： 10.1016/j.ijcard.2012.12.031

Source DB: PubMed Journal: Int J Cardiol ISSN： 0167-5273 Impact factor: 4.164

Keyword Cloud
Cited

× No keyword cloud information.

13 in total

1. Prolonged activation of IL-5-producing ILC2 causes pulmonary arterial hypertrophy.

Authors: Masashi Ikutani; Koichi Tsuneyama; Makoto Kawaguchi; Junya Fukuoka; Fujimi Kudo; Susumu Nakae; Makoto Arita; Yoshinori Nagai; Satoshi Takaki; Kiyoshi Takatsu
Journal: JCI Insight Date: 2017-04-06

2. Noninvasive Prognostic Biomarkers for Left-Sided Heart Failure as Predictors of Survival in Pulmonary Arterial Hypertension.

Authors: Catherine E Simpson; Rachel L Damico; Paul M Hassoun; Lisa J Martin; Jun Yang; Melanie K Nies; R Dhananjay Vaidya; Stephanie Brandal; Michael W Pauciulo; Eric D Austin; D Dunbar Ivy; William C Nichols; Allen D Everett
Journal: Chest Date: 2020-01-25 Impact factor: 9.410

3. ST2 Is a Biomarker of Pediatric Pulmonary Arterial Hypertension Severity and Clinical Worsening.

Authors: Megan Griffiths; Jun Yang; Catherine E Simpson; Dhananjay Vaidya; Melanie Nies; Stephanie Brandal; Rachel Damico; D Dunbar Ivy; Eric D Austin; Michael W Pauciulo; Katie A Lutz; Erika B Rosenzweig; Russel Hirsch; Delphine Yung; William C Nichols; Allen D Everett
Journal: Chest Date: 2021-02-18 Impact factor: 10.262

4. Soluble ST2 as a Biomarker for Early Complications in Patients with Chronic Thromboembolic Pulmonary Hypertension Treated with Balloon Pulmonary Angioplasty.

Authors: Marta Banaszkiewicz; Arkadiusz Pietrasik; Michał Florczyk; Piotr Kędzierski; Michał Piłka; Rafał Mańczak; Janusz Kochman; Grzegorz Opolski; Adam Torbicki; Marcin Kurzyna; Szymon Darocha
Journal: Diagnostics (Basel) Date: 2021-01-16

Serum soluble ST2 and interleukin-33 levels in patients with pulmonary arterial hypertension.

1. Prolonged activation of IL-5-producing ILC2 causes pulmonary arterial hypertrophy.

2. Noninvasive Prognostic Biomarkers for Left-Sided Heart Failure as Predictors of Survival in Pulmonary Arterial Hypertension.

3. ST2 Is a Biomarker of Pediatric Pulmonary Arterial Hypertension Severity and Clinical Worsening.

4. Soluble ST2 as a Biomarker for Early Complications in Patients with Chronic Thromboembolic Pulmonary Hypertension Treated with Balloon Pulmonary Angioplasty.

5. Alteration of the IL-33-sST2 pathway in hypertensive patients and a mouse model.

Review 6. Biomarkers for pediatric pulmonary arterial hypertension - a call to collaborate.

7. The Prognostic Value of Soluble ST2 in Adults with Pulmonary Hypertension.

Review 8. Circulating Blood-Based Biomarkers in Pulmonary Hypertension.

9. Soluble ST2 as a Potential Biomarker in Pericardial Fluid of Coronary Artery Patients.

10. Soluble ST2 and mixed venous oxygen saturation for prediction of mortality in patients with pulmonary hypertension.